Chromosomal aberrations induced by imipramine and desipramine in mouse.
Imipramine (IMI) and desipramine (DES) are two drugs widely used for the treatment of depression as well as for other diseases. In the present study, we determined their capacity to induce chromosomal aberrations in mouse bone marrow cells. Three doses of each compound were tested and their results were compared with the frequency of chromosomal aberrations obtained in a control group as well as with a group treated with cyclophosphamide. Our results showed a significant increase in chromosome damage with the doses tested for each compound: 7, 20, and 60 mg/kg in the case of IMI, and 2, 20, and 60 mg/kg as regards DES. This last drug induced stronger chromosomal damage than IMI. Our results agree with previous studies regarding the induction of micronuclei and sister chromatid exchanges by the drugs in mouse and suggest caution with respect to their use in long-term treatments.
Madrigal-Bujaidar
E
E
Laboratorio de Genética. Escuela Nacional de Ciencias Biologicas, IPN, Mexico. eduardo.madrigal@lycos.com
Cárdenas García
Y
Y
Alvarez-González
I
I
D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000633:toxicity*; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000473:pathology; D002869:Chromosome Aberrations / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000633:toxicity*; D003891:Desipramine / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D007099:Imipramine / Q000633:toxicity*; D008297:Male; D051379:Mice
D000929:Antidepressive Agents, Tricyclic; D003520:Cyclophosphamide; D007099:Imipramine; D003891:Desipramine